| Dr Harbans Singh Hans, MD | |
|
120 Aspen Cir, Torrington, WY 82240-3703 | |
| (720) 383-1731 | |
| (307) 532-6676 |
| Full Name | Dr Harbans Singh Hans |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 38 Years |
| Location | 120 Aspen Cir, Torrington, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336362680 | NPI | - | NPPES |
| 121569800 | Medicaid | WY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 5553A (Wyoming) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Uhs Of Wyoming, Inc | 9830111442 | 11 |
News Archive
The Clinton Foundation HIV/AIDS Initiative and UNITAID on Monday announced that they have negotiated agreements with generic drug companies that will reduce the cost of some antiretroviral drugs and provide new pediatric formulations, the Wall Street Journal reports.
The American Academy of Child and Adolescent Psychiatry (AACAP) is proud to announce its new Practice Parameter on issues related to and affecting gay, lesbian, bisexual, and gender variant youth.
According to recent statistics, LifeNet Health was able to distribute 40,040 allograft bio-implants to patients in November 2009, an unprecedented number in LifeNet Health's 27-year history.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 5 days ago
| Entity Name | Uhs Of Wyoming, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295709822 PECOS PAC ID: 9830111442 Enrollment ID: O20060109000787 |
News Archive
The Clinton Foundation HIV/AIDS Initiative and UNITAID on Monday announced that they have negotiated agreements with generic drug companies that will reduce the cost of some antiretroviral drugs and provide new pediatric formulations, the Wall Street Journal reports.
The American Academy of Child and Adolescent Psychiatry (AACAP) is proud to announce its new Practice Parameter on issues related to and affecting gay, lesbian, bisexual, and gender variant youth.
According to recent statistics, LifeNet Health was able to distribute 40,040 allograft bio-implants to patients in November 2009, an unprecedented number in LifeNet Health's 27-year history.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Harbans Singh Hans, MD 120 Aspen Cir, Torrington, WY 82240-3703 Ph: (720) 383-1731 | Dr Harbans Singh Hans, MD 120 Aspen Cir, Torrington, WY 82240-3703 Ph: (720) 383-1731 |
News Archive
The Clinton Foundation HIV/AIDS Initiative and UNITAID on Monday announced that they have negotiated agreements with generic drug companies that will reduce the cost of some antiretroviral drugs and provide new pediatric formulations, the Wall Street Journal reports.
The American Academy of Child and Adolescent Psychiatry (AACAP) is proud to announce its new Practice Parameter on issues related to and affecting gay, lesbian, bisexual, and gender variant youth.
According to recent statistics, LifeNet Health was able to distribute 40,040 allograft bio-implants to patients in November 2009, an unprecedented number in LifeNet Health's 27-year history.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 5 days ago